<p>瑞穗证券分析师 Graig Suvannavejh 今天对 Axsome Therapeutics 维持了买入评级，并设定了 310.00 美元的目标价。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Suvannavejh 覆盖医疗保健行业，关注 Insmed、Verastem 和 Immuneering 等股票。根据 TipRanks 的数据，Suvannavejh 的平均回报率为 19.9%，推荐股票的成功率为 48.98%。</p>
<p>除了瑞穗证券，Axsome Therapeutics 还在今天的报告中获得了 H.C. Wainwright 的 Ram Selvaraju 的买入评级。然而，在同一天，摩根士丹利对 Axsome Therapeutics（NASDAQ: AXSM）维持了持有评级。</p>

AXSM

<p>瑞穗证券分析师 Graig Suvannavejh 对 Axsome Therapeutics (AXSM) 维持买入评级，目标价为 310.00 美元。Suvannavejh 专注于医疗保健行业，其股票推荐的平均回报率为 19.9%，成功率为 48.98%。此外，H.C. Wainwright 的 Ram Selvaraju 也对 Axsome Therapeutics 发布了买入评级，而摩根士丹利则对该股票维持持有评级</p>

<p>Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics today and set a price target of $310.00.</p>
<div class="lb-trans"><p>瑞穗证券分析师 Graig Suvannavejh 今天对 Axsome Therapeutics 维持了买入评级，并设定了 310.00 美元的目标价。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Suvannavejh covers the Healthcare sector, focusing on stocks such as Insmed, Verastem, and Immuneering. According to TipRanks, Suvannavejh has an average return of 19.9% and a 48.98% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Suvannavejh 覆盖医疗保健行业，关注 Insmed、Verastem 和 Immuneering 等股票。根据 TipRanks 的数据，Suvannavejh 的平均回报率为 19.9%，推荐股票的成功率为 48.98%。</p>
</div><p>In addition to Mizuho Securities, Axsome Therapeutics also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued today. However, on the same day, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).</p>
<div class="lb-trans"><p>除了瑞穗证券，Axsome Therapeutics 还在今天的报告中获得了 H.C. Wainwright 的 Ram Selvaraju 的买入评级。然而，在同一天，摩根士丹利对 Axsome Therapeutics（NASDAQ: AXSM）维持了持有评级。</p>
</div>

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Tip Ranks

Axsome Therap

Mizuho Financial Group, Inc.

瑞穗金融集团

Insmed

Verastem

Immuneering

摩根士丹利

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

瑞穗证券维持对 Axsome Therapeutics（AXSM）的买入评级